Phase 1 Studies of CD19 CAR T Cell Immunotherapy for Large B Cell Lymphoma

Explore the cutting-edge field of CAR-T cell immunotherapy through this 27-minute webinar presented by Professor Cameron Turtle, a leading expert in cancer immunotherapy from the University of Sydney. Delve into the innovative approach of using genetically modified T cells expressing chimeric antigen receptors (CARs) targeted to CD19 for treating patients with relapsed and refractory large B cell lymphomas. Learn about the comprehensive series of phase 1/2 clinical trials that investigate how CD19 CAR-T cells are manufactured from distinct T cell subsets and formulated in defined compositions for patient infusion. Discover the critical factors that impact treatment outcomes, including the novel combination of exogenous IL-15 support with CD19 CAR-T therapy and the strategic timing of anti-PD-L1 therapy when combined with CAR-T treatment. Gain insights into the lymphodepletion chemotherapy process that precedes CAR-T cell infusion and examine correlative research findings that advance our understanding of this revolutionary cancer treatment. Master the identification of key outcome predictors, understand the results from trials combining IL-15 with CAR-T therapy, and analyze the optimal timing strategies for anti-PD-L1 combination treatments in large B cell lymphoma patients.